Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amarendra Pegu

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
Science Translational Medicine|September 14, 2021
Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concernHyeseon Cho, Kristina Kay Gonzales-Wartz, Deli Huang, et al.
Biorxiv : the Preprint Server for Biology|April 6, 2021
Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variantsHyeseon Cho, Kristina Kay Gonzales-Wartz, Deli Huang, et al.
Science (New York, N.Y.)|January 30, 2025
Pre-exposure antibody prophylaxis protects macaques from severe influenzaMasaru Kanekiyo, Rebecca A Gillespie, Kristine Cooper, et al.
The Lancet. HIV|September 2, 2019
Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trialMartin R Gaudinski, Katherine V Houser, Nicole A Doria-Rose, et al.
Science (New York, N.Y.)|July 20, 2022
Broadly neutralizing antibodies target the coronavirus fusion peptideCherrelle Dacon, Courtney Tucker, Linghang Peng, et al.
Biorxiv : the Preprint Server for Biology|April 20, 2022
Broadly neutralizing antibodies target the coronavirus fusion peptideCherrelle Dacon, Courtney Tucker, Linghang Peng, et al.
Cell Reports|January 5, 2022
Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeysAmarendra Pegu, Ling Xu, Megan E DeMouth, et al.
Biorxiv : the Preprint Server for Biology|August 19, 2022
A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralizationJohn Misasi, Ronnie R Wei, Lingshu Wang, et al.
JCI Insight|April 8, 2024
Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LSSeemal F Awan, Amarendra Pegu, Larisa Strom, et al.
Journal of Virology|August 22, 2014
Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivoRebecca S Rudicell, Young Do Kwon, Sung-Youl Ko, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
Science Translational Medicine|September 14, 2021
Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concernHyeseon Cho, Kristina Kay Gonzales-Wartz, Deli Huang, et al.
Biorxiv : the Preprint Server for Biology|April 6, 2021
Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variantsHyeseon Cho, Kristina Kay Gonzales-Wartz, Deli Huang, et al.
Science (New York, N.Y.)|January 30, 2025
Pre-exposure antibody prophylaxis protects macaques from severe influenzaMasaru Kanekiyo, Rebecca A Gillespie, Kristine Cooper, et al.
The Lancet. HIV|September 2, 2019
Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trialMartin R Gaudinski, Katherine V Houser, Nicole A Doria-Rose, et al.
Science (New York, N.Y.)|July 20, 2022
Broadly neutralizing antibodies target the coronavirus fusion peptideCherrelle Dacon, Courtney Tucker, Linghang Peng, et al.
Biorxiv : the Preprint Server for Biology|April 20, 2022
Broadly neutralizing antibodies target the coronavirus fusion peptideCherrelle Dacon, Courtney Tucker, Linghang Peng, et al.
Cell Reports|January 5, 2022
Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeysAmarendra Pegu, Ling Xu, Megan E DeMouth, et al.
Biorxiv : the Preprint Server for Biology|August 19, 2022
A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralizationJohn Misasi, Ronnie R Wei, Lingshu Wang, et al.
JCI Insight|April 8, 2024
Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LSSeemal F Awan, Amarendra Pegu, Larisa Strom, et al.
Journal of Virology|August 22, 2014
Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivoRebecca S Rudicell, Young Do Kwon, Sung-Youl Ko, et al.
Pageof 9